Case report of 3 patients with severe mental illness and chronic hepatitis C virus infection treated with interferon-alpha

International Journal of Psychiatry in Medicine

Volumn 36, Issue 4, 2006, Pages 449-455

  Mistler, Lisa A ^a,d   Brunette, Mary F ^b   Rosenberg, Stanley D ^a   Vidaver, Robert M ^a   Luckoor, Ravi ^c   Iber, Mark ^c  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b DARTMOUTH PSYCHIATRIC RESEARCH CENTER   (United States)

^c New Hampshire Hospital   (United States)

^d VA MEDICAL CENTER   (United States)

Author keywords

Depression; Hepatitis C; Interferon; Severe mental illness

Indexed keywords

ALPHA INTERFERON; AMFEBUTAMONE; ANTIVIRUS AGENT; BENZATROPINE; CARBAMAZEPINE; FLUOXETINE; LAMOTRIGINE; LORAZEPAM; MESORIDAZINE; OLANZAPINE; PEGINTERFERON; PERPHENAZINE; RIBAVIRIN; RISPERIDONE; SERTRALINE; TRAZODONE; TRIFLUOPERAZINE; ALPHA2A INTERFERON; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; MACROGOL DERIVATIVE; NEUROLEPTIC AGENT; PEGINTERFERON ALFA-2A; PEGINTERFERON ALPHA2A; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ALCOHOLISM; ARTICLE; BECK DEPRESSION INVENTORY; BIPOLAR DISORDER; BIPOLAR I DISORDER; BLOOD EXAMINATION; CASE REPORT; DEPRESSION; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; FATTY LIVER; FEMALE; GENETIC VARIABILITY; GROUP THERAPY; HEPATITIS C; HEPATITIS C VIRUS; HOSPITALIZATION; HUMAN; HYPOPARATHYROIDISM; HYPOTHYROIDISM; INSOMNIA; INSULIN DEPENDENT DIABETES MELLITUS; LEUKOCYTE COUNT; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER NECROSIS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION; PSYCHIATRIST; RECREATIONAL THERAPY; SCHIZOAFFECTIVE PSYCHOSIS; SIDE EFFECT; SUBSTANCE ABUSE; TREATMENT RESPONSE; ALCOHOLICS ANONYMOUS; COMORBIDITY; DRUG COMBINATION; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATIENT CARE; VIRUS LOAD;

ADULT; ALCOHOLICS ANONYMOUS; ALCOHOLISM; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; ANTIVIRAL AGENTS; BIPOLAR DISORDER; COMBINED MODALITY THERAPY; COMORBIDITY; DRUG THERAPY, COMBINATION; FEMALE; FLUOXETINE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; PATIENT CARE TEAM; POLYETHYLENE GLYCOLS; RIBAVIRIN; TRIAZINES; VIRAL LOAD;

EID: 34250313711     PISSN: 00912174     EISSN: 15413527     Source Type: Journal    
DOI: 10.2190/1336-74M1-1718-73G1     Document Type: Article

References (23)

1. Rosenberg SD, Goodman LA, Osher FC, Swartz MS, Essock SM, Butterfield MI, Constantine NT, Wolford GL, Salyers MP. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. American Journal of Public Health 2001; 91(1):31-37.
2. Meyer, J. M. Prevalence of hepatitis A, hepatitis B, and HIV among hepatitis C-seropositive state hospital patients: Results from Oregon State Hospital. Journal of Clinical Psychiatry 2003;64(5):540-545.
3. Fried M, Schiffman M, Reddy R, Smith C, Marinos G, Goncales F, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Pegylated (40kDa) (PEGASYS) interferon alfa-2a in combination with ribavirin: Efficacy and safety results from a phase III, randomized, actively controlled multicenter study. Gastroenterology 2001;120:A55.
4. Manns MP, McHutchinson JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribaviran compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001;358:958-965.
5. Mistler LA, Brunette MF, Marsh BJ, Vidaver RM, Luckoor R, Rosenberg SD. (2006). Hepatitis C treatment for people with severe mental illness. Psychosomatics March-April 2006;47(2):93-107.
6. Strader DB. (2002). Understudied populations with hepatitis C. Hepatology 2002;36(5):S226-S236.
7. Taylor LE, Costello T, Alt E, Yates G, Tashima K. Psychiatric illness and illicit drugs as barriers to hepatitis C treatment among HIV/hepatitis virus co-infected individuals. AIDS 2002;16(12): 1700-1701.
8. Fleming CA, Craven DE, Thornton D, Tumilty S, Nunes D. (2003). Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: Low eligibility for interferon treatment. Clinical Infectious Diseases 2003;36(1):97-100.
9. Janssen HL, Brouwer JT, van der Mast RC, Schalm SW. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. Journal of Hepatology 1994;21:241-243.
10. Iancu I, Sverdlik A, Dannon PN, Lepkifker E. Bipolar disorder associated with interferon-alpha treatment. Postgraduate Medical Journal 1997;73:834-835.
11. Kanno A, Yamada M, Abe M, Okamoto Y. A case of interferon-alpha induced manic psychosis in chronic hepatitis C. Tohuku Journal of Expimental Medicine 1999; 187:79-82.
12. Strite D, Valentine AD, Meyers CA. Manic episodes in two patients treated with interferon alpha. Journal of Neuropsychiatry & Clinical Neurosciences 1997;9:273-276.
13. Nozaki O, Takagi C, Takaoka K, Takata T, Yoshida M. Psychiatric manifestations accompanying interferon therapy for patients with chronic hepatitis C: An overview of cases in Japan. Psychiatry & Clinical Neurosciences 1997;51:175-180.
14. Greenberg DB, Jonasch E, Gadd MA, Ryan BF, Everett JR, Sober AJ, Mihm MA, Tanabe KK, Ott M, Haluska FG. Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes. Cancer 2000;89:356-362.
15. Bozikas V, Petrikis P, Balla A, Karavatos A. An interferon-alpha-induced psychotic disorder in a patient with chronic hepatitis C. European Psychiatry: The Journal of the Association of European Psychiatrists 2001;16:136-137.
16. Van Thiel DH, Friedlander L, Molloy PJ, Fagiuoli S, Kania RJ, Caraceni P. (1995). "Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness. European Journal of Gastroenterology & Hepatology 1995;7(2):165-168.
17. Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindbeck N, Heldwein W, Soyka M, Grunze H, Koenig A, Loeschke K. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003;37(2):443-451.
18. Pariante C, Orru M, Baita A, Farci M, Carpiniello B. Treatment with interferon alpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet 1997;354:131-132.
19. Sylvestre D, Djavaherian C, Clements B. The impact of psychiatric disease on HCV outcomes in methadone maintenance patients. At Schering Hepatitis Investigators' Network VI. Orlando, FL, 2002.
20. Hensley ML, Peterson B, Silver RT, Larson RA, Schiffer CA, Szatrowski TP. Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: Analysis of Cancer and Leukemia Group B 9013. Journal of Clinical Oncology 2000;18:1301-1308.
21. Ho S, Nguyen H, Tetrick L, Opitz G, Basara M, Dieperink E. (2001). "Influence of psychiatric diagnosis on interferon-alpha treatment for chronic hepatitis C in a veteran population. American Journal of Gastroenterology 2001;96:157-164.
22. Hauser P, Soler R, Reed S, Kane R, Gulati M, Khosla J, Kling MA, Valentine AD, Meyers CA. Prophylactic treatment of depression induced by interferon-alpha. Psychosomatics 2000;41(5):439-441.
23. Dobmeier M, Frick E, Frank S, Franke C, Wolfersdorf M. Schizophrenic psychosis: A contraindication for treatment of hepatitis C with interferon alpha? Pharmacopsychiatry 2000;33(2):72-74.